

Hong Kong brings next-gen experimental platform for assisted reproduction

29 March 2021 | News

World's first embryonic single-cell level automated sequencing system combines artificial intelligence data analysis and automatic report generation system



Suzhou Become Medical Co., Ltd. ("Become Medical") and Shenzhen Hua Dazhi Manufacturing Technology Co., Ltd. ("MGI") have reached a strategic cooperation in sequencer research and development. Become Medical's Chairman Dr. Liang Bo, R&D Director Mr. Kong Lingyin and MGI's President Mr. Yu Dejian attended the signing ceremony.

Both parties Committed to joint development of the next-generation automated experimental platform solutions for assisted reproduction.

Among them, MGI, as the world's leading R&D and manufacturer of sequencers in the field of life sciences, will develop localized sequencing technology based on embryonic single-cell level sequencing: Beikang Medical will be based on the world's leading embryonic single-cell amplification SDWGA technology and the first domestic product.

The operation process of the PGT kit that has obtained the national three-class medical device registration certificate, develops the world's first embryonic single-cell level automated sequencing system, combines artificial intelligence data analysis and automatic report generation system to create an integrated next-generation automated experimental platform for assisted reproduction solution.

Beikang Medical plans to invest 430 million yuan in the field of assisted reproduction in the next 5 years to build an integrated overall experimental platform solution from detection to storage, to achieve automated gene sequencing and automated ultra-low temperature storage at the embryonic single-cell level, and complete PGT-M and PGT -SR clinical registration of two test kits, construction of a three-category medical device registration product pipeline and automated laboratory platform solutions covering the entire reproductive cycle.